Safety and Efficacy Study of VIS649 for IgA Nephropathy
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants With Immunoglobulin A (IgA) Nephropathy A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Eff ...
Immunoglobulin A Nephropathy;Glomerular Disease;IgAN
Drug: Dose-Placebo;Drug: Low Dose-VIS649;Drug: Medium Dose-VIS649;Drug: High Dose-VIS649
Visterra, Inc.
NULL
Active, not recruiting
18 Years
N/A
All
155
Phase 2
United States;Australia;Canada;Hong Kong;India;Japan;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sri Lanka;Taiwan;Thailand;United Kingdom United States;Australia;Canada;Hong Kong;India;Japan;Korea, Republic of;Malaysia;Philippines;Singapo ...
A study to look at the effect and how safe drug VIS649 is in patients with kidney disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants with Immunoglobulin A (IgA) Nephropathy A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Eff ...
Immunoglobulin A (IgA) Nephropathy MedDRA version: 20.0;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Immunoglobulin A (IgA) Nephropathy MedDRA version: 20.0;Level: PT;Classification code 10021263;Term: ...
Product Name: VIS649 Product Code: VIS649 INN or Proposed INN: VIS649 Other descriptive name: VIS649 Product Name: VIS649 Product Code: VIS649 INN or Proposed INN: VIS649 Other descriptive name: VIS649 Product Name: VIS649 Product Code: VIS649 INN or Proposed INN: VIS649 Other descriptive name: VIS649Product Name: VIS649 Product Code: VIS649 INN or Proposed INN: VIS649 Other descriptive name: VIS649 Pro ...
Visterra, Inc.
NULL
Authorised-recruitment may be ongoing or finished
Female: yes Male: yes
144
Phase 2
United States;Philippines;Hong Kong;Taiwan;Thailand;Spain;United Kingdom;India;Czech Republic;Canada;Malaysia;Singapore;Australia;Japan;Korea, Republic of United States;Philippines;Hong Kong;Taiwan;Thailand;Spain;United Kingdom;India;Czech Republic;Canada ...
First in Human Study to Assess Safety of VIS649 in Healthy Subjects
A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of VIS649 Administered Intravenously in Healthy Subjects A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose First-in-Human Study to Assess the ...
Immunoglobulin A Nephropathy;IgAN - IgA Nephropathy;IgA Nephropathy